In the period studied 150 patients underwent one or more YAG laser iridotomies. Of these patients 40 (27%) were treated for acute angle closure glaucoma, 13 (9%) for subacute angle closure glaucoma, 44 (29%) for chronic glaucoma in which the anterior chamber angles were felt to be pathologically narrow, 17 (11%) for iris bombs (most often due to pseudophakia or posterior synechiae), 22 (15%) for prophylaxis on narrow angles, 3 (2%) for phacogenic glaucoma, and one after silicone oil insertion. Information could not be obtained on 10
Laser iridotomy has gained widespread favour over surgical iridectomy because of factors such as avoidance of retrobulbar anaesthesia, maintenance of the anterior chamber, absence of risk of infective endophthalmitis, and application as an outpatient procedure. Nd-YAG is considered preferable over argon because of lower total energy requirements,' greater ease of iris penetration independent of iris colour,2 and a lower incidence of iridotomy closure. 34 The long term safety of argon iridotomy compares favourably with that of surgery,5 and initial concern about cataract formation with YAG iridotomy has not been confirmed. 67 This study was undertaken to review the short term results of YAG laser iridotomies for AACG since its introduction in Bristol in 1984, and to assess the efficacy of iridotomies by provocative testing of a selected group of patients.
Material and methods
For the purposes of this study acute Three eyes (7-5%) suffered recurrent AACG, at a maximum post-YAG interval of six weeks, and all had previously undergone more than one YAG iridotomy. The first eye was still receiving pilocarpine when the patient presented again, and the iridotomy looked patent. A trabeculectomy was carried out. The iridotomy of the second eye did not look patent, and a further iridotomy was performed. Iris bleeding occurred, and this iridotomy was also imperforate. Following a peripheral iridectomy the IOP became normal without any medications. The original iridotomy of the third eye was judged small at an early follow-up appointment, and the patient soon developed recurrent AACG. After a further YAG iridotomy the IOP was normal on no treatment.
Sixteen patients attended for provocative testing, with 16 acute and 15 fellow eyes being tested (Table  2) . One patient did not stay for the required two hours, but was negative in both eyes at 1 hour. Three patients were still using pilocarpine, but all achieved the required pupil dilatation. In the 15 eyes with acute glaucoma the average pupil diameter rose from 2-75 mm to 3-85 mm at 2 hours, and the average lOP was 15-4 mmHg initially and 14.3 mmHg after two hours. In the 14 fellow eyes the average pupil diameter rose from 2-47 mm to 3-48 mm after two hours, and the average IOP changed from 15-3 mmHg to 13-3 mmHg. In none of the 29 eyes tested did the IOP rise more than 2 mmHg. In two eyes the maximum pupil diameter was 2-75 mm; all the other eyes achieved a pupil diameter of 3 mm or greater.
Discussion
Laser iridotomy has become an attractive alternative to surgical peripheral iridectomy in the treatment of AACG. One advantage of Nd-YAG over argon has been the smaller number of repeat iridotomies needed.4 However, 48% of the eyes with acute glaucoma and 18% of fellow eyes required retreat-R H Gray, J Hoare Nairne, and W H R Ayliffe ment, well above the 9% quoted by Schwartz et The increased incidence of iris bleeding in acute eyes (16% compared to 3% in fellow eyes) is consistent with their engorged iris vasculature, yet the number is small compared with one reported study of 45% . 4 These eyes, however, were monitored for five minutes at the slit-lamp after the iridotomy, which was not the case in our study.
Analysis of the available clinical data did not reveal any factors that would be predictive of the number of laser procedures required. When those requiring only one procedure were compared with those needing more than one procedure, the average length of acute attack was found to be 2-6 days in the former and 1.82 in the latter. Similarly, presenting TOPs were almost identical in the two groups. Although iris colour was not analysed, previous studies have not shown darker irides to be more difficult to penetrate with the YAG laser.' 3 Nineteen eyes with acute glaucoma have required no further treatment after YAG iridotomy(ies). For this group the average IOP at presentation and the average length of acute attack were 57 mmHg and 3-3 days respectively. This compares with values of 55 mmHg and 2-8 days for the remaining 19 eyes with acute glaucoma requiring further medical or surgical treatment. These figures do not indicate that length of acute attack increases the risk of chronic angle closure glaucoma developing, and lend support to the policy of delaying iridotomy until IOP has been reduced.
Recurrent AACG does not appear to be a significant risk after surgical peripheral iridectomy,9 '0 but was an important complication after YAG iridotomy in our series. The three eyes that developed recurrent AACG had undergone more than iridotomy at the time of their first attack, but when they presented again it was clear in two that the iridotomy was imperforate. A further YAG iridotomy was carried out on one, and a peripheral iridectomy on the other, and neither of these eyes required further treatment. The third eye had a plateau iris configuration, and the patient presented again despite a clinically patent iridotomy. A trabeculectomy was carried out.
Closure of Nd-YAG iridotomies was not observed in one reported study3 of 38 patients with acute or chronic angle closure glaucoma over a mean period of 15 months, patency being verified in these patients by direct inspection of the iridotomy site. A report of a larger series2 of 200 Nd-YAG iridotomies describes two closures during a mean follow-up of 9 3 months, these occurring in patients with pre-existing chronic uveitis. It is likely that in one of our three recurrences the iridotomy was imperforate from the outset, but it is possible that in one patient the iridotomy closed later. This is well recognised with argon laser iridotomies.' The third eye developed recurrent AACG in the presence of a clinically patent iridotomy, an observation consistent with the diagnosis of plateau iris made at that time.
Clinical assessment of iridotomy patency may be made in a number of ways. Direct observation of the crystalline lens or vitreous through the iridotomy is certainly more reliable than iris retroillumination in this respect. We consider that Nd-YAG iridotomies are a safe and effective treatment for AACG, but there is a small and significant risk of recurrence. Routine clinical methods may not identify those at risk, and therefore we advocate the routine use of Mapstone's test to help identify this group. We suggest that it be incorporated into the early follow-up of patients as soon as ocular hypotensive medications have been discontinued.
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